GMP BIO Co.,LTD

PIPELINE

Overview
Classification	PIPELINE		Candidate material	Preclinical	Clinical trial			New Drug approval	Item authorization
Classification	PIPELINE		Candidate material	Preclinical	1	2	3	New Drug approval	Item authorization
Cell therapy (*Treg cell)	Alzhimer's disease	VT301
Cell therapy (*Treg cell)		VT301	Technology transfer completed (Kyung Hee university) Completed Pre-clinical of Chemon (KOSDAQ-Listed Company), a domestic GLP company U.S. Clinical Phase 1 and Phase 2a will be entered simultaneously Under IND review of the Korea Clinical Phase 1
Botanical medicine		VT012 (PM012)
		VT012 (PM012)	Clinical Phase 2 completed (Korea's Ministry of Food and Drug Safety(MFDS)) Clinical Phase 2b/3 in progress
	*COPD VT014 (PM014)	Acute upper respiratory infection
		Acute upper respiratory infection	Clinical Phase 3 completed Item authorization in progress
		*COPD
		*COPD	Clinical Phase 2 cost 12 billion Clinical Phase 3 cost 200 billion estimate
	Depression VT011(PM011)
	Depression VT011(PM011)		MFDS individually-approved functional food Item authorization in progress
	Alopecia / Depilation VT015
	Alopecia / Depilation VT015		Preclinical efficacy completed Human application test in progress
Botanical functional material (Health functional food)	Regulation of blood glucose VT021(PM021)
Botanical functional material (Health functional food)	Regulation of blood glucose VT021(PM021)		Individually-approved health functional food Item authorization (2010-33)

*COPD: chronic obstructive pulmonary disease*Treg: immune-regulatory T cell